Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$56.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 11.65% year-over-year to -$56.7 million in Q1 2026; TTM through Mar 2026 was -$207.8 million, a 19.46% decrease from a year earlier, with the FY2025 full-year figure at -$201.9 million, up 23.68% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$56.7 million, down from -$48.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RYTM reached as high as -$33.6 million in Q2 2024 and fell as low as -$141.4 million in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged -$52.6 million across 5 years, with a median of -$47.4 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders slumped 226.48% in 2022 and surged 64.05% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$42.5 million in 2022, then advanced by 2.02% to -$41.6 million in 2023, then fell by 7.2% to -$44.6 million in 2024, then dropped by 9.42% to -$48.8 million in 2025, then retreated by 16.19% to -$56.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$56.7 million in Q1 2026, -$48.8 million in Q4 2025, and -$54.3 million in Q3 2025.